Estrella Immunopharma, Inc.
ESLANext catalyst
EB103
B-Cell Non-Hodgkin's Lymphoma (NHL)
Get an email about ESLA's next catalysts
Track Estrella Immunopharma (ESLA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 0 past
EB103 Phase 2 Est. Readout (STARLIGHT-1)
Primary completion for EB103 trial (NCT06343311) in B-Cell Non-Hodgkin's Lymphoma (NHL)
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EB103 | Phase 2 | B-Cell Non-Hodgkin's Lymphoma (NHL) | - | - |
Frequently asked questions
What is in Estrella Immunopharma, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Estrella Immunopharma, Inc.'s (ESLA) pipeline across Phase 2. Its lead program is EB103 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Estrella Immunopharma, Inc.'s next FDA catalyst?→
Estrella Immunopharma, Inc.'s (ESLA) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ESLA biotech catalysts?→
Add ESLA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Estrella Immunopharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.